Tag: file

LAS VEGAS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Lingerie Fighting Championships, Inc. (“LFC”) (OTC Pink:BOTY) announced today that they have up-listed to the newly created OTCID market. In order to do so they had to meet all criteria including be fully SEC reporting, be in good standing with state and federal regulators, retain a recognized transfer agent and file a Company Verified Profile and Management Certification with the OTC.

BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it now holds approximately 1,293,562 SOL and SOL equivalents on its balance sheet, inclusive of rewards generated through staking and onchain activities. The increase follows the Company’s purchase of 110,466 SOL at an average purchase price of $166.61, representing a total value of approximately $18.4 million.

Elme to Seek Shareholder Approval for Cortland Portfolio Transaction and Plan of Sale and Liquidation

Company Announcement No 64/2025  

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Semler Scientific, Inc. (NASDAQ: SMLR) resulting from allegations that Semler Scientific may have issued materially misleading business information to the investing public.

NORWELL, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. (“DIH” or the “Company”) (NASDAQ:DHAI) received a notice on July 29, 2025, from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”), which stated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not filed its Annual Report on Form 10-K for the period ended March 31, 2025 with the Securities and Exchange Commission (“SEC”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the SEC.

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.

En s’appuyant sur les résultats de faisabilité du projet financé par RNCan, l’équipe du projet vise désormais à achever la conception technique préliminaire de trois installations destinées à convertir les déchets de bois en carburant diesel renouvelable